{"id":38656,"date":"2026-06-01T09:12:00","date_gmt":"2026-06-01T13:12:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38656"},"modified":"2026-05-03T13:44:20","modified_gmt":"2026-05-03T17:44:20","slug":"should-you-file-a-provisional-patent-for-your-drug-invention-the-honest-answer","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/should-you-file-a-provisional-patent-for-your-drug-invention-the-honest-answer\/","title":{"rendered":"Should You File a Provisional Patent for Your Drug Invention? The Honest Answer"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Every week, a medicinal chemistry team somewhere identifies a promising compound, runs it past the IP group, and asks a version of the same question: do we file a provisional patent now or wait until we know more?<\/p>\n\n\n\n

The standard answer from IP counsel is almost always some variant of “file early.” And in a first-to-file system, that instinct is correct as far as it goes. But the standard answer leaves out the part that actually decides whether a provisional patent application (PPA) helps or destroys your drug program: the quality of what you put in it.<\/p>\n\n\n\n

This article is for R&D leads, IP strategists, and drug development executives who need a working understanding of how provisional patent applications function in pharmaceutical contexts\u2014not a general overview, but a decision framework they can apply to real programs. It covers when to file, what to put in a provisional, what happens when the disclosure is inadequate, how the 20-year clock interacts with your FDA timeline, and what competitor intelligence services like DrugPatentWatch reveal about how the industry actually uses these filings in practice.<\/p>\n\n\n\n

The stakes are not abstract. Between 2025 and 2030, approximately 190 drugs\u2014including roughly 70 blockbusters generating over $1 billion in annual sales\u2014face patent expiration<\/a>, putting an estimated $236 billion to $300 billion in annual revenue at risk [1]. The foundations of those patent portfolios were laid in provisional applications filed one, two, sometimes three decades ago. The decisions made in those early filings still control market outcomes today.<\/p>\n\n\n\n

\n

“The average capitalized cost to bring a single new drug to market can exceed $2.6 billion, with recent figures placing the average at $2.23 billion in 2024.” \u2014 DrugPatentWatch, The Patent Cliff Playbook<\/em> [2]<\/p>\n<\/blockquote>\n\n\n\n

When that much capital rides on one compound, the cost of a $1,500 provisional filing fee is irrelevant. The cost of a defective provisional\u2014one that fails to adequately describe the eventual claims\u2014can be the entire program.<\/p>\n\n\n\n

\n\n\n\n

What a Provisional Patent Application Actually Is (and Is Not)<\/strong><\/h2>\n\n\n\n

A provisional patent application is a United States Patent and Trademark Office (USPTO) filing that establishes a priority date without initiating the formal examination process. It requires a specification and drawings where necessary, but does not require formal patent claims, inventor oaths or declarations, or an information disclosure statement<\/a> [3]. The USPTO filing fee ranges from $65 to $325 as of January 2025, depending on entity size.<\/p>\n\n\n\n

The provisional application expires automatically 12 months after filing if the applicant does not convert it to a non-provisional (utility) application. It does not result in a granted patent on its own. No examination of patentability occurs. The provisional simply sits in the USPTO system, establishing a timestamp.<\/p>\n\n\n\n

That timestamp\u2014the priority date\u2014is everything.<\/p>\n\n\n\n

In a first-to-file patent system, the priority date determines who wins when two inventors claim the same or overlapping territory. For pharmaceutical compounds, where two competing research programs can independently identify the same target and similar chemical series, being one week earlier at the USPTO can decide who gets the patent. The priority date also defines what counts as prior art against your application: disclosures made before your priority date can invalidate your patent; disclosures made after it generally cannot.<\/p>\n\n\n\n

What a provisional is not: a shortcut. The provisional filing provides a priority date only for what it adequately describes<\/a> [4]. File a thin provisional to grab an early date and then claim inventions in your non-provisional that weren’t properly disclosed in the provisional, and you lose the benefit of the earlier date for those claims. In pharmaceutical litigation, that gap becomes the target.<\/p>\n\n\n\n

\n\n\n\n

The 20-Year Clock and Why Timing Is a Financial Decision<\/strong><\/h2>\n\n\n\n

U.S. patents on pharmaceutical inventions run 20 years from the earliest effective non-provisional filing date. Not from the provisional. Not from FDA approval. From the non-provisional filing.<\/p>\n\n\n\n

This creates a structural problem for drug developers. A substantial portion of the patent term\u2014often 10 to 15 years\u2014gets consumed by preclinical research, multi-phase clinical trials, and regulatory review<\/a> [2]. By the time a drug reaches patients, the composition-of-matter patent covering the active ingredient may have only 8 to 12 years of remaining life.<\/p>\n\n\n\n

A provisional application introduces a critical nuance here. Filing a provisional does not start the 20-year clock. The clock starts when you file the non-provisional application<\/a> [5]. This means the 12-month provisional window is genuinely free time from a patent term perspective. You can spend that year running additional biological assays, refining your synthetic route, gathering pharmacokinetic data, and drafting claims that reflect what the compound actually does\u2014all while your priority date sits secured at the earlier date.<\/p>\n\n\n\n

Patent Term Adjustment and Extension: The Downstream Compensation Mechanisms<\/strong><\/h3>\n\n\n\n

Two statutory mechanisms partially compensate for the time lost between filing and market entry: Patent Term Adjustment (PTA) and Patent Term Extension (PTE).<\/p>\n\n\n\n

PTA, available under 35 U.S.C. \u00a7 154(b), adds days to a patent’s term when the USPTO causes prosecution delays\u2014for example, failing to respond to an application within prescribed timeframes. PTA adjustments accumulate during examination and are calculated by the USPTO at issuance. For pharmaceutical applications, which are technically complex and often subject to lengthy prosecution, PTA awards of two to four years are not uncommon.<\/p>\n\n\n\n

PTE, available under the Hatch-Waxman Act at 35 U.S.C. \u00a7 156, restores some patent term lost during FDA regulatory review for drugs, medical devices, and veterinary products<\/a> [6]. The maximum extension is five years, with total post-approval exclusivity capped at 14 years. Only one patent per approved product qualifies for PTE, and the applicant must file within 60 days of FDA approval\u2014a deadline that is non-extendable.<\/p>\n\n\n\n

Together, PTA and PTE can restore meaningful exclusivity. But they don’t change the underlying arithmetic: the earlier you file your non-provisional, the earlier the 20-year clock starts ticking, and the less time your patent covers the commercial period. Filing the non-provisional too early wastes patent term before the drug reaches market; filing too late risks losing priority to a competitor filing on a similar compound<\/a> [5].<\/p>\n\n\n\n

The provisional application is the mechanism that lets you delay the non-provisional filing without sacrificing the priority date. That’s its primary value proposition.<\/p>\n\n\n\n

\n\n\n\n

The Written Description Requirement: Where Provisional Applications Fail<\/strong><\/h2>\n\n\n\n

This is the section most overviews skip. It is also the section that separates pharmaceutical IP strategy from wishful thinking.<\/p>\n\n\n\n

To receive the benefit of a provisional filing date, the non-provisional application must show that the provisional adequately described the claimed invention. The controlling statute is 35 U.S.C. \u00a7 112(a), which requires that a patent specification contain a written description of the invention sufficient to convince a person having ordinary skill in the art that the inventor had possession of the claimed invention at the time of filing.<\/p>\n\n\n\n

In the “unpredictable arts”\u2014which includes chemistry and pharmaceuticals\u2014a very detailed description is required<\/a> [7]. This is a materially higher standard than what applies to software or mechanical inventions, where a flow chart or schematic can be sufficient. In pharmaceutical contexts, the unpredictability of biological systems means that a compound described only by its structural class or general mechanism of action may not satisfy the written description requirement for specific therapeutic claims made years later.<\/p>\n\n\n\n

Purdue Pharma v. Iancu: The ‘Blaze Marks’ Problem<\/strong><\/h3>\n\n\n\n

The Federal Circuit’s non-precedential decision in Purdue Pharma L.P. v. Iancu<\/em> illustrates how a seemingly robust provisional can fail. The patent at issue, U.S. Patent 9,034,376, covered controlled release oral dosage forms of oxycodone. The court found that the provisional application disclosed a ‘laundry list’ of possible gelling agents\u2014including polyethylene oxide (PEO) and hydroxypropylmethylcellulose (HPMC)\u2014but provided no ‘blaze marks’ pointing to the specific combination claimed in the issued patent<\/a> [8].<\/p>\n\n\n\n

Because the claims weren’t adequately supported by the provisional, they didn’t receive its priority date. Intervening prior art then invalidated them.<\/p>\n\n\n\n

The lesson is not that provisional applications are dangerous. The lesson is that listing a broad genus of compounds or excipients in a provisional, without specifically identifying the combination that will eventually be claimed, fails to support narrow species claims in the non-provisional. In pharmaceutical patent prosecution, where Markush claims covering chemical genera are common, and where the inventive combination is often a specific subset of a disclosed class, this distinction is commercially material.<\/p>\n\n\n\n

The 2025 Federal Circuit Trend: Tightening Disclosure Standards<\/strong><\/h3>\n\n\n\n

The risk is not historical. In consecutive weeks in late 2025, the Federal Circuit reversed two jury verdicts totaling over $80 million in pharmaceutical patent disputes, holding in both cases that the specifications failed, as a matter of law, to satisfy \u00a7 112(a)’s disclosure requirements<\/a> [9]. The cases\u2014Seagen Inc. v. Daiichi Sankyo<\/em> and Duke University v. Sandoz Inc.<\/em>\u2014signal an increasing judicial willingness to treat patent specifications as legal texts subject to independent judicial interpretation rather than factual questions for juries.<\/p>\n\n\n\n

For pharmaceutical IP teams, this trend has an immediate practical implication: the written description standard for pharmaceutical patents is being enforced more aggressively, at the appellate level, and in ways that override jury findings. A provisional application that would have survived scrutiny a decade ago may not survive it today.<\/p>\n\n\n\n

New Railhead: The Foundational Warning<\/strong><\/h3>\n\n\n\n

In New Railhead Manufacturing, LLC v. Vermeer Mfg. Co.<\/em>, 298 F.3d 1290 (Fed. Cir. 2002), the Federal Circuit established that the written description and enablement requirements of 35 U.S.C. \u00a7 112 apply equally to provisional and non-provisional applications<\/a> [10]. The distinction in formality between a provisional and a non-provisional application does not create a distinction in the substantive disclosure obligation.<\/p>\n\n\n\n

This case remains the most cited authority for the proposition that a provisional application cannot be a placeholder for an invention the applicant hasn’t yet conceived. The disclosure in the provisional must match\u2014in substantive terms\u2014what is eventually claimed.<\/p>\n\n\n\n

\n\n\n\n

When to File a Provisional: The Decision Framework<\/strong><\/h2>\n\n\n\n

The question “should you file a provisional?” resolves to a more specific question: do you have enough right now to enable your eventual claims?<\/p>\n\n\n\n

For drug inventions, the answer depends on the type of invention and the stage of development.<\/p>\n\n\n\n

Composition-of-Matter Patents: File at First Credible Reduction to Practice<\/strong><\/h3>\n\n\n\n

A composition-of-matter patent covering a new chemical entity (NCE) or new biological entity (NBE) is the most valuable patent in any pharmaceutical portfolio. These patents cover the active ingredient itself, including its salts, esters, and polymorphs, and are the most difficult for generic competitors to design around<\/a> [11]. When this patent survives intact, it controls the entire market regardless of what formulations or indications competitors develop.<\/p>\n\n\n\n

File a provisional for a composition-of-matter claim when you have characterized the compound structurally, identified at least preliminary evidence of biological or therapeutic activity, and can describe the compound in enough detail that a skilled chemist could synthesize it. You don’t need Phase II clinical data. You need enough to establish possession of the specific compound at a specific priority date.<\/p>\n\n\n\n

What you cannot do is file a provisional covering a broad chemical genus and then claim priority to it for a specific compound within that genus that you identified after the provisional filing date. The written description requirement for a claimed genus requires sufficient description of a representative number of species, either by actual reduction to practice, by disclosure of relevant identifying characteristics such as structure or physical and chemical properties, or by functional characteristics coupled with a known correlation between function and structure<\/a> [12]. Filing a broad genus provisional to capture future compounds is not a supported strategy under current Federal Circuit doctrine.<\/p>\n\n\n\n

Formulation Patents: File When the Concept Is Clear<\/strong><\/h3>\n\n\n\n

Secondary patents on formulations\u2014controlled release systems, specific excipient combinations, drug delivery platforms\u2014represent a different timing decision. The best strategy is to apply for provisional patents as soon as the formulation concept becomes clear<\/a> [13]. The 12-month window then gives the development team time to optimize the formulation, gather stability data, and prepare the kind of detailed non-provisional specification that will survive Paragraph IV challenge.<\/p>\n\n\n\n

Formulation patents filed too early\u2014before the specific excipient ratios, particle sizes, or release profiles that define the commercial product are characterized\u2014create the exact problem the Purdue Pharma case illustrates: a disclosure that mentions the right components but doesn’t point to the right combination.<\/p>\n\n\n\n

Formulation patents filed too late\u2014after a competitor has filed on a similar system or after public disclosure has occurred\u2014lose their priority position. The practical answer is to file when the inventive combination is identified and characterized, not when it is fully optimized, and to use the 12-month window for optimization.<\/p>\n\n\n\n

Method-of-Use Patents: File When Indication-Specific Data Exists<\/strong><\/h3>\n\n\n\n

Method-of-use patents protect a specific therapeutic application of a known compound. They’re patentable when the use is not obvious from the compound’s known properties and when the specification supports the claimed utility. For a new compound, method-of-use claims can accompany the composition-of-matter provisional. For a compound entering clinical development for a new indication, a separate provisional keyed to that indication makes sense once preliminary clinical data exists.<\/p>\n\n\n\n

The enablement challenge for method-of-use claims in pharmaceuticals is significant. In the unpredictable arts, a very detailed description is required<\/a> [7], and for method-of-use claims asserting therapeutic efficacy, courts and the USPTO expect the specification to demonstrate or strongly predict that efficacy. Claiming a method of treating a disease with a compound that shows only in vitro activity\u2014without in vivo data\u2014creates enablement vulnerability that generic challengers will exploit at PTAB or in district court.<\/p>\n\n\n\n

Process and Manufacturing Patents: File with Full Synthetic Detail<\/strong><\/h3>\n\n\n\n

Process patents covering synthetic routes to active pharmaceutical ingredients or manufacturing methods for biologics are typically filed at a more advanced stage of development, when the process is actually characterized. The provisional for a manufacturing process needs to disclose the actual steps, conditions, reagents, and yields\u2014not a general description of a synthetic approach. Vague process claims are easy for generic manufacturers to design around, and an inadequately described provisional provides no useful priority date for the specific process that ultimately appears in the commercial product.<\/p>\n\n\n\n

\n\n\n\n

The Rolling Provisional Strategy: Building Priority Over Time<\/strong><\/h2>\n\n\n\n

For pharmaceutical programs where the invention evolves iteratively, the “rolling provisional” strategy offers a structured approach to maintaining an expanding priority position.<\/p>\n\n\n\n

By filing successive provisional applications that incorporate new subject matter as it emerges, a company can continuously update and expand its priority claim<\/a> [14]. Each new provisional establishes a priority date for the newly added subject matter. The non-provisional application, filed within 12 months of the earliest provisional, claims the benefit of all provisionals in the series.<\/p>\n\n\n\n

Consider a concrete example. A company identifies a lead compound and files Provisional 1 with structural characterization and in vitro activity data in month one. In month six, new metabolic stability data clarifies which salt form is preferred; they file Provisional 2 adding this data. In month nine, an in vivo efficacy study validates the mechanism; they file Provisional 3. In month twelve, they convert to a non-provisional claiming benefit of all three provisionals. The non-provisional can claim the specific salt form covered by Provisional 2 with Provisional 2’s priority date, and the method-of-use supported by Provisional 3’s in vivo data with Provisional 3’s priority date.<\/p>\n\n\n\n

This approach requires coordination between the IP team and R&D, but it produces a layered priority position that is much harder to attack than a single provisional that attempts to anticipate all future claims. The key discipline is that each new provisional must genuinely disclose new subject matter\u2014you cannot use a rolling provisional series to update or rehabilitate inadequate disclosure from an earlier filing.<\/p>\n\n\n\n

\n\n\n\n

The International Dimension: Paris Convention and PCT Filing Windows<\/strong><\/h2>\n\n\n\n

A U.S. provisional application establishes a priority date that you can claim in international filings under the Paris Convention, provided you file those applications within 12 months of the provisional.<\/p>\n\n\n\n

This creates a compressed timeline for programs with global commercial ambitions. You have 12 months from the U.S. provisional to file PCT (Patent Cooperation Treaty) applications or direct national phase applications in foreign jurisdictions. If you convert the provisional to a non-provisional at month 12 and simultaneously file a PCT application, you’ve used the full window. If you convert at month 10 to add two months for PCT prosecution, you’ve given up two months of non-provisional patent term.<\/p>\n\n\n\n

The grace period question complicates international strategy further. Many jurisdictions have specific grace period regulations\u2014for example, Argentina allows a one-year grace period for disclosures made by the inventor, while countries like the Czech Republic, Denmark, and Finland offer a six-month grace period under particular conditions<\/a> [15]. The European Patent Office, where most pharmaceutical companies seek protection, has a very narrow grace period that does not cover most public disclosures. Any public disclosure before an international filing date\u2014including a conference presentation, a preprint, or even a conversation that doesn’t qualify as confidential\u2014can destroy European patent rights for the disclosed subject matter.<\/p>\n\n\n\n

This means pharmaceutical programs with European aspirations need provisional-to-PCT timelines that are tighter than the U.S.-only timeline, and they need strict disclosure controls that prevent inadvertent prior art creation before the provisional filing.<\/p>\n\n\n\n

\n\n\n\n

What Drug Patent Intelligence Reveals About Provisional Filing Patterns<\/strong><\/h2>\n\n\n\n

Understanding how the industry actually uses provisional applications requires access to patent filing data at scale. DrugPatentWatch<\/a> provides pharmaceutical competitive intelligence that tracks provisional applications, non-provisional conversions, and Orange Book listings for drugs across all therapeutic categories. Analysts and IP teams use this data to map competitor programs, identify freedom-to-operate risks, and time their own filings relative to the competitive landscape.<\/p>\n\n\n\n

A provisional patent application filed with the USPTO becomes publicly available 18 months after its filing date<\/a> [16]. This creates an 18-month intelligence gap between when a company files a provisional and when the public can see what was disclosed. For competitive intelligence purposes, the gap matters: by the time a competitor’s provisional becomes visible, the filer has already converted to a non-provisional and potentially filed international applications, building a patent family that may take years to prosecute to issuance.<\/p>\n\n\n\n

For R&D teams at pharmaceutical companies, DrugPatentWatch’s tracking of pending applications\u2014including applications not yet published\u2014provides early signals about competitor programs based on the progression of prior art in adjacent chemical and biological spaces. When a competitor’s provisional application publishes, the detailed technical disclosure it contains often reveals the state of their program at the time of filing, the specific compounds under development, and the therapeutic rationale they were pursuing\u2014sometimes months before the company makes any public announcement about the program.<\/p>\n\n\n\n

What the Data Shows About Big Pharma Provisional Filings<\/strong><\/h3>\n\n\n\n

Companies with sophisticated IP operations don’t treat provisional filings as one-off events. They treat them as the first move in a multi-year portfolio construction process. A single NCE program at a major pharmaceutical company will typically generate provisionals covering the composition of matter, preferred salt forms, lead formulation approaches, primary indication, and key manufacturing process steps\u2014filed in sequence as each element is characterized, and all claimed in the non-provisional.<\/p>\n\n\n\n

Smaller biotechnology companies, which are the primary exit targets for large pharma acquisitions, face a different pressure. PPAs enable inventors to test their inventions or present them to potential investors without committing to full disclosure. This is particularly beneficial for biotechnology and drug discovery startups that seek funding or partnerships to advance their inventions<\/a> [15]. The “patent pending” status that a provisional confers creates a shield for fundraising conversations, allowing the company to discuss its chemistry with potential partners without triggering prior art issues in the United States.<\/p>\n\n\n\n

That shield has limits. It only works if the confidential discussions remain genuinely confidential\u2014a signed CDA is necessary but not sufficient if the discussion creates a public prior art reference in a foreign jurisdiction. And the shield provides no protection if the provisional itself is inadequate and the eventual non-provisional claims can’t benefit from the provisional’s priority date.<\/p>\n\n\n\n

\n\n\n\n

The Cost Calculation: What You’re Actually Paying For<\/strong><\/h2>\n\n\n\n

The nominal cost of a provisional patent application is low by pharmaceutical standards. As of 2025, USPTO fees for a provisional application range from $65 for micro entities to $325 for large entities. Attorney preparation fees for a well-drafted pharmaceutical provisional typically run from $5,000 to $15,000 depending on complexity and the firm involved. That’s the direct cost.<\/p>\n\n\n\n

The indirect cost calculation is different. A well-drafted provisional that establishes a defensible priority date for a composition-of-matter patent on a successful drug is worth, in revenue terms, every day of exclusivity it buys. When a blockbuster drug’s key patents expire and generic competitors enter the market, the innovator can see its market share plummet by over 80%, with drug prices falling by as much as 90%<\/a> [17]. The Hatch-Waxman framework moves fast once generic entry begins: the 180-day exclusivity period for the first ANDA filer creates a short window before branded prices collapse.<\/p>\n\n\n\n

For a drug generating $2 billion annually, each day of additional exclusivity is worth roughly $5.5 million in revenue. A provisional that captures a priority date three months earlier than a competitor’s filing, and that survives litigation challenge, could be worth $500 million or more in preserved revenue. The filing fee is not the relevant cost variable.<\/p>\n\n\n\n

The relevant cost variable is the attorney time required to draft a provisional that will actually hold up. Filing a minimally described provisional to save attorney fees is rational only if the claims you eventually want to make are fully supported by that minimal disclosure\u2014which, in pharmaceutical contexts, they almost never are.<\/p>\n\n\n\n

\n\n\n\n

Provisional Applications and the Hatch-Waxman Litigation System<\/strong><\/h2>\n\n\n\n

For drugs listed in the FDA’s Orange Book, the provisional application’s downstream effects play out most visibly in Hatch-Waxman litigation.<\/p>\n\n\n\n

The Paragraph IV certification mechanism allows generic manufacturers to challenge listed patents prior to NDA expiry<\/a> [18]. When a generic filer submits an ANDA with a Paragraph IV certification asserting that an Orange Book-listed patent is invalid or not infringed, the brand company can file suit within 45 days and trigger a 30-month automatic stay of ANDA approval. This 30-month period is where the adequacy of the original patent disclosure\u2014including the provisional that supported the priority date\u2014gets fully stress-tested.<\/p>\n\n\n\n

Generic challengers in Paragraph IV litigation routinely attack the written description and enablement of pharmaceutical patents. When a drug’s composition-of-matter patent was filed provisionally with thin disclosure and converted to a non-provisional that expanded the claims, the gap between provisional disclosure and issued claims becomes exhibit one for the challenger. The question the court asks is whether the provisional provided adequate written description for the claims as issued\u2014and, as the Purdue Pharma case shows, even well-resourced companies with experienced IP teams can lose that argument.<\/p>\n\n\n\n

The 30-month stay is valuable\u2014it preserves revenue during the litigation period\u2014but it is not guaranteed. Generic challengers can move for a preliminary injunction or declaratory judgment, and in cases where the underlying patents have obvious vulnerability, generic entry can happen faster. Companies that filed weak specifications or failed to document their invention comprehensively during development watch their patents collapse under administrative challenge before any generic even reaches the market<\/a> [19].<\/p>\n\n\n\n

A robust provisional\u2014one that documents every feature of the eventual claims with specificity\u2014is not litigation insurance. But it is a prerequisite for litigation viability.<\/p>\n\n\n\n

\n\n\n\n

Biologics and Biosimilars: How Provisional Filing Strategy Differs<\/strong><\/h2>\n\n\n\n

Provisional patent strategy for biological drugs carries additional complexity. The patent landscape for biologics is layered more aggressively than for small molecules, and the interplay between patent term and 12-year FDA data exclusivity for biologics creates different optimization constraints.<\/p>\n\n\n\n

Patent term and data exclusivity are independent and run concurrently. The 12-year exclusivity clock starts on the day of FDA approval, regardless of when the relevant patents were filed or when they will expire<\/a> [20]. A biologic’s composition-of-matter patent can expire while the product still has FDA data exclusivity remaining, meaning the biosimilar manufacturer cannot reference the innovator’s data even after the patent falls. Conversely, data exclusivity can expire years before key manufacturing or formulation patents do.<\/p>\n\n\n\n

For biologics, provisional applications covering the composition of matter\u2014the antibody sequence, the protein structure, the cell line\u2014must be filed with sufficient specificity to support claims to those exact molecules. The written description requirement is enforced with particular severity for biological inventions claiming broad genus coverage. The Juno Therapeutics v. Kite Pharma<\/em> line of Federal Circuit decisions has progressively tightened the written description requirement for antibody claims that attempt to cover functional characteristics without disclosing representative structural embodiments [21].<\/p>\n\n\n\n

This creates a practical pressure for biologic developers: file provisionals that describe specific antibody sequences, specific binding characteristics, and specific in vitro activity data\u2014not just functional definitions of what the antibody does. The provisional for a biologic is structurally more demanding to write well than the provisional for a small molecule, and the attorney time and preparation costs reflect that.<\/p>\n\n\n\n

For biosimilar manufacturers, provisional patent filings by innovators are a competitive intelligence source. When an innovator files a provisional covering a new formulation or manufacturing process for a biologic approaching patent expiration, that filing signals an attempt to extend the effective exclusivity window beyond the composition-of-matter expiry. Biosimilar manufacturers monitoring these filings through services like DrugPatentWatch can time their own ANDA or 351(k) application strategies to challenge the secondary patents before they become commercially inconvenient.<\/p>\n\n\n\n

\n\n\n\n

The Inventor Disclosure and IP Committee Process: Operationalizing Early Filing<\/strong><\/h2>\n\n\n\n

The decision to file a provisional doesn’t happen in isolation. In pharmaceutical companies of any size, it happens inside an IP management process that connects R&D laboratory notebooks, patent counsel review, and IP committee approval. The quality of that process determines whether provisional filings are strategically timed or merely reactive.<\/p>\n\n\n\n

Best practice in pharmaceutical IP management starts with inventor disclosure forms that capture not just what was discovered but when it was reduced to practice, what prior art the inventors are aware of, and what future developments are anticipated. This documentation creates the contemporaneous record of conception and reduction to practice that supports both the provisional filing and any later priority date dispute.<\/p>\n\n\n\n

The IP committee review process at well-run pharmaceutical companies includes a forward-looking patent coverage analysis: what claims will we want in three years, and does our provisional today support those claims? This exercise forces earlier and more specific provisional drafting than a typical “let’s file something to get a date” approach produces. IP teams that engage with R&D and commercial strategy from the earliest stages of discovery, rather than entering the picture at the IND stage, capture meaningfully more exclusivity per asset<\/a> [22].<\/p>\n\n\n\n

For startup biotechnology companies, the IP committee equivalent is a conversation between the founding scientists and IP counsel before the first conference abstract is submitted. The most common and most avoidable error in early-stage biotech IP management is public disclosure before provisional filing\u2014presenting data at a scientific meeting, publishing a preprint, or posting results on a company website before the priority date is secured.<\/p>\n\n\n\n

\n\n\n\n

AI-Assisted Drug Discovery and Provisional Patent Inventorship<\/strong><\/h2>\n\n\n\n

AI-assisted drug discovery introduces a new layer of provisional filing complexity that wasn’t in the framework five years ago.<\/p>\n\n\n\n

In February 2024, the USPTO issued guidance clarifying that AI-assisted inventions are patentable, provided that one or more humans made a ‘significant contribution’ to the conception of the invention<\/a> [23]. The guidance specifies that significant contribution could involve designing, building, or training the AI model for a specific problem, or curating the specific data used to train the model.<\/p>\n\n\n\n

For provisional applications filed by drug discovery teams using generative AI platforms to screen chemical space or predict binding affinities, the inventorship documentation becomes more complex. The provisional must name the correct human inventors\u2014those who made significant contributions to the conception of the specific compounds being claimed\u2014not the scientists who ran the AI platform that generated candidates without specific direction. Getting inventorship wrong on a provisional, and then carrying that error into the non-provisional, creates validity risk that generic challengers will find.<\/p>\n\n\n\n

The practical guidance for AI-assisted drug discovery provisionals is to document, at the time of filing, exactly what the human scientists conceived versus what the AI generated, and what human judgment was applied in selecting and characterizing the eventual compounds. This documentation supports the eventual inventorship determination and provides a contemporaneous record that cannot be reconstructed years later when litigation begins.<\/p>\n\n\n\n

\n\n\n\n

Provisional Applications as Competitive Intelligence Signals<\/strong><\/h2>\n\n\n\n

The 18-month publication timeline for provisional applications creates an intelligence asymmetry that sophisticated pharmaceutical competitors exploit systematically.<\/p>\n\n\n\n

When a competitor’s provisional application publishes, it contains a detailed technical disclosure of the state of their program as of the filing date. For programs in therapeutic areas where your company competes, this disclosure tells you which compounds they were pursuing, what biological targets they had validated, what clinical indications they were developing toward, and what manufacturing approaches they had characterized\u2014all documented in the legal language of a patent specification, which tends to be more technically complete than a scientific paper.<\/p>\n\n\n\n

DrugPatentWatch aggregates this published provisional data alongside issued patents, Orange Book listings, ANDA filing histories, and litigation records to give pharmaceutical IP teams a structured view of the competitive landscape. When used prospectively, this intelligence can inform your own provisional filing timing\u2014filing before a competitor publishes on overlapping chemistry, or identifying gaps in the published competitive landscape that your program can exploit.<\/p>\n\n\n\n

For institutional investors evaluating pharmaceutical companies, provisional application filings are an underutilized signal. A biotech that has filed provisionals covering composition of matter, preferred formulations, and primary indication with 18 months of rolling coverage has materially better IP infrastructure than a company that hasn’t filed yet or filed a single thin provisional. The gap between those two profiles isn’t visible in the company’s financials, but it shows up in patent databases\u2014and it correlates with the company’s ability to defend its exclusivity when generic or biosimilar challengers eventually appear.<\/p>\n\n\n\n

\n\n\n\n

The Five Most Common Provisional Filing Mistakes in Drug Development<\/strong><\/h2>\n\n\n\n

Based on the case law and the documented failure modes of pharmaceutical patent prosecution, five mistakes account for the majority of provisional application problems in drug development programs.<\/p>\n\n\n\n

1. Filing a Genus Without Species Examples<\/strong><\/h3>\n\n\n\n

Filing a provisional that describes a Markush structure covering a broad class of compounds, without characterizing specific working examples within that class, satisfies the written description requirement for the genus only to the extent that the disclosure demonstrates possession of the full genus. If you subsequently want to claim a specific compound within the genus, the provisional needs to specifically identify and characterize that compound. Broad genus provisionals that don’t support specific species claims are a structural weakness that appears in pharmaceutical patent invalidation proceedings regularly.<\/p>\n\n\n\n

2. Using the Provisional as a Research Agenda<\/strong><\/h3>\n\n\n\n

A provisional that describes what you hope to discover or what experiments you plan to run does not establish a priority date for the discoveries you eventually make. The provisional must describe what you have, not what you intend to have. If applicants file provisional applications quickly to save money, they may find themselves without the priority date the provisional application was intended to provide, and, in the worst case, with no patent protection at all<\/a> [4].<\/p>\n\n\n\n

3. Failing to Include Structural Data for Biological Inventions<\/strong><\/h3>\n\n\n\n

For monoclonal antibodies, fusion proteins, and other biologics, a provisional that defines the invention purely by functional characteristics\u2014”an antibody that binds to target X and inhibits function Y”\u2014without providing sequence data or structural characterization invites written description challenges under the post-Juno<\/em> Federal Circuit doctrine. If you have the sequence data at filing time, include it. If you don’t, the provisional is premature for those specific claims.<\/p>\n\n\n\n

4. Missing the International Filing Window<\/strong><\/h3>\n\n\n\n

Filing a U.S. provisional and then failing to file PCT or national phase applications within the 12-month window destroys international patent rights for that subject matter. In therapeutic areas where the global market is essential to drug development economics, losing European, Japanese, or Chinese rights because the PCT deadline was missed is a serious and preventable error.<\/p>\n\n\n\n

5. Failing to Update the Provisional with New Data<\/strong><\/h3>\n\n\n\n

The rolling provisional strategy exists to solve a real problem: drug development is iterative, and the best data for enabling claims often comes after the first provisional filing. Teams that file a single provisional and then wait 12 months to convert\u2014without adding new data as it develops\u2014often find themselves converting with claims that outrun the original disclosure. Filing continuation provisionals as new data emerges keeps the disclosure and the intended claims aligned throughout the development window.<\/p>\n\n\n\n

\n\n\n\n

Decision Tree: Should You File a Provisional Now?<\/strong><\/h2>\n\n\n\n

If you’re working on a drug invention and trying to decide whether to file a provisional application today, the following questions provide a structured framework.<\/p>\n\n\n\n

First: is there a risk of public disclosure, whether through a paper submission, conference presentation, or partnership discussion, within the next 30 days? If yes, file before that disclosure occurs. U.S. law provides a one-year grace period from inventor disclosure, but international filing rights depend on pre-disclosure filing in most jurisdictions. If international rights matter to your program, the answer is to file before any disclosure.<\/p>\n\n\n\n

Second: have you characterized the invention specifically enough to support the eventual claims? If you can describe the compound’s structure and demonstrate at least preliminary activity, you have enough for a composition-of-matter provisional. If you’re still generating structural data, wait until you have it\u2014but not past the first disclosure risk.<\/p>\n\n\n\n

Third: is there a competitor who might be working in the same chemical or biological space? If yes, file as soon as you have adequate disclosure. The first-to-file rule doesn’t reward the team that waits for perfection; it rewards the team that files first with adequate disclosure.<\/p>\n\n\n\n

Fourth: do you have budget and counsel to draft a complete provisional? A poorly drafted provisional filed without experienced pharmaceutical patent counsel is worse than a delayed filing in many circumstances\u2014it creates a false sense of security while establishing a priority date that won’t survive challenge. The investment in counsel to draft a substantive provisional is not optional for drug inventions with commercial potential.<\/p>\n\n\n\n

\n\n\n\n

What ‘Patent Pending’ Actually Signals to the Market<\/strong><\/h2>\n\n\n\n

The commercial significance of “patent pending” status extends beyond legal protection. For pharmaceutical startups, the provisional filing status signals to acquirers, investors, and partners that the company has taken the formal step of securing a priority date for its core invention.<\/p>\n\n\n\n

Pharmaceutical M&A due diligence consistently includes IP review that examines whether key assets have filed provisional applications, how robust those provisionals are, and what the gap looks like between the provisional disclosure and the claims the company intends to pursue. A program where the composition-of-matter provisional was filed with complete structural characterization and in vitro activity data, backed up by subsequent provisionals adding formulation and method-of-use coverage, presents a fundamentally different risk profile than a program with a single provisional filed before any biological data existed.<\/p>\n\n\n\n

Institutional investors analyzing pharmaceutical company valuations can access the patent filing record\u2014including provisional publication dates and non-provisional conversion timelines\u2014through services like DrugPatentWatch. The gap between provisional filing date and non-provisional conversion date tells an experienced analyst whether the IP team filed early and developed the disclosure during the provisional window, or filed late and compressed the non-provisional preparation. Both patterns carry information about how the company manages IP risk.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n
    \n
  • A provisional patent application establishes a priority date without starting the 20-year patent term clock, giving pharmaceutical programs a 12-month development window at a relatively low filing cost\u2014but only if the provisional adequately describes the eventual claims under 35 U.S.C. \u00a7 112(a).<\/li>\n\n\n\n
  • The written description requirement applies equally to provisionals and non-provisionals. Thin provisionals that describe broad genera without specific working examples, or that list multiple options without identifying the claimed combination, do not provide valid priority dates for narrowly claimed inventions\u2014a vulnerability the Federal Circuit has increasingly enforced as a matter of law, overriding jury findings, as recently as late 2025.<\/li>\n\n\n\n
  • The rolling provisional strategy\u2014filing successive provisionals as new data develops, then claiming benefit of the entire series in the non-provisional\u2014is the appropriate tool for iterative drug development programs. Each new provisional captures a priority date for genuinely new subject matter, not a rehabilitation of inadequate prior disclosure.<\/li>\n\n\n\n
  • International rights require attention to the 12-month Paris Convention window. Provisional applications filed in the U.S. support international priority only if PCT or national phase applications are filed within 12 months of the provisional’s filing date. In most jurisdictions, any public disclosure before the international filing date destroys those rights.<\/li>\n\n\n\n
  • For biologics, AI-assisted drug discovery programs, and complex formulation inventions, the standards for adequate provisional disclosure are technically demanding and require experienced pharmaceutical patent counsel. The attorney time required to draft a substantive provisional is the key cost variable\u2014not the USPTO filing fee.<\/li>\n\n\n\n
  • Pharmaceutical competitive intelligence platforms like DrugPatentWatch track provisional application filings, publication timelines, and conversion patterns, allowing IP teams and investors to map competitor programs, time their own filings, and assess the IP infrastructure of drug development companies before acquisition or investment decisions.<\/li>\n\n\n\n
  • For the roughly $300 billion in pharmaceutical revenue entering the patent cliff between now and 2030, the patent portfolios defending that revenue were built on provisional applications filed years ago. The quality of those provisionals\u2014how specifically they described what they eventually claimed\u2014now determines the timeline of generic and biosimilar entry for drugs that millions of patients depend on.<\/li>\n<\/ul>\n\n\n\n
    \n\n\n\n

    Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

    Q1: Can you file a provisional patent application if you only have in vitro data and no animal or clinical data yet?<\/strong><\/h3>\n\n\n\n

    Yes, and for composition-of-matter claims on a new chemical entity, you often should. The written description and enablement requirements don’t demand clinical efficacy data for a provisional to establish a valid priority date for composition claims. You need enough to show that a person skilled in the art would understand you had possession of the specific compound\u2014which typically means structural characterization and at least preliminary evidence of biological activity. What you cannot do is file a provisional claiming broad therapeutic utility when you have only structural data and then later assert that the provisional supports specific method-of-use claims based on clinical trial results. The priority date for those method-of-use claims will be the date when the supporting data was actually included in a filing.<\/p>\n\n\n\n

    Q2: If a competitor publishes a scientific paper on a compound similar to yours before your provisional filing, does that automatically destroy your patent rights?<\/strong><\/h3>\n\n\n\n

    Not automatically, but it creates serious problems that depend on timing and scope. Under U.S. law, you have a one-year grace period from a third-party disclosure to file your own application on your independent invention. However, if the competitor’s paper discloses the same compound you want to claim, that prior art establishes that the compound was known before your filing date, which will likely defeat novelty. If the paper discloses a related compound but not the specific compound you’re claiming, the analysis shifts to non-obviousness: was your specific compound obvious from the disclosed compound plus the general knowledge in the field? For pharmaceutical compounds, the unpredictability of structure-activity relationships often supports non-obviousness arguments, but this is fact-specific and expensive to litigate. The correct answer, operationally, is to file before competitors publish on adjacent chemistry\u2014which requires active monitoring of the scientific literature and a defined trigger for provisional filing in your IP management process.<\/p>\n\n\n\n

    Q3: What happens to a provisional patent application if the company that filed it gets acquired before converting to a non-provisional?<\/strong><\/h3>\n\n\n\n

    The provisional application is an assignable asset and transfers to the acquiring company as part of the acquisition. The acquirer steps into the shoes of the original filer, including all rights and obligations associated with the provisional. They have the same 12-month window from the provisional’s filing date to convert to a non-provisional. If the acquisition closes six months after the provisional was filed, the acquirer has six months remaining to convert. This timeline is a standard element of pharmaceutical M&A due diligence: buyers identify all pending provisional applications and their conversion deadlines, assess whether the disclosures are adequate for the intended claims, and make immediate decisions about whether to proceed with conversion or file additional provisionals. A provisional that was filed thinly by a cash-constrained startup and never supplemented will need substantial bolstering before a sophisticated acquirer converts it to a non-provisional with commercially useful claims.<\/p>\n\n\n\n

    Q4: Can a pharmaceutical company file a provisional patent application on a drug formulation that is already described in a published patent owned by someone else?<\/strong><\/h3>\n\n\n\n

    A provisional on formulation elements already claimed in an existing patent won’t give you anything useful\u2014you’d be claiming subject matter that isn’t yours to claim. However, pharmaceutical formulation patents are more nuanced than this framing suggests. If an existing patent covers one formulation approach and you’ve developed a different formulation\u2014different excipients, different release mechanism, different manufacturing process\u2014that may be independently patentable even if it achieves similar clinical results. Freedom-to-operate analysis is distinct from patentability: you need to analyze whether your formulation practices the claims of existing patents (freedom-to-operate) separately from whether your formulation is novel and non-obvious over the prior art (patentability). A provisional on your new formulation is appropriate if it’s genuinely novel; whether you can commercialize the formulation without a license is a separate analysis that a provisional filing doesn’t resolve.<\/p>\n\n\n\n

    Q5: How does the patent term extension calculation work for a drug whose composition-of-matter patent was filed as a provisional?<\/strong><\/h3>\n\n\n\n

    Patent Term Extension (PTE) under the Hatch-Waxman Act calculates from the date of the non-provisional application filing, not the provisional. The PTE period is based on the length of the regulatory review period\u2014the time between when the IND went effective and when the NDA was approved\u2014adjusted by a testing phase calculation. The maximum extension is five years, capped such that the remaining patent term after approval doesn’t exceed 14 years. Because the provisional filing doesn’t start the 20-year clock, a drug whose non-provisional was filed several months after the provisional, and whose regulatory review consumed 10 or more years, will typically qualify for the maximum five-year PTE. The practical implication is that using the full 12-month provisional window before converting to a non-provisional generally doesn’t cost you PTE eligibility\u2014but it does mean the 20-year clock starts 12 months later, which matters for the tail end of the patent term when the PTE ceiling might otherwise cap your total exclusivity.<\/p>\n\n\n\n

    \n\n\n\n

    References<\/strong><\/h2>\n\n\n\n
      \n
    1. Alcimed. (2025). Patent cliff: What strategies can help biopharma stay competitive?<\/em> https:\/\/www.alcimed.com\/en\/insights\/patent-cliff\/<\/li>\n\n\n\n
    2. DrugPatentWatch. (2025). The patent cliff playbook: A strategic guide to tracking and capitalizing on pharmaceutical loss of exclusivity.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/the-patent-cliff-playbook-a-strategic-guide-to-tracking-and-capitalizing-on-pharmaceutical-loss-of-exclusivity\/<\/li>\n\n\n\n
    3. Wikipedia. (2025). Provisional application.<\/em> https:\/\/en.wikipedia.org\/wiki\/Provisional_application<\/li>\n\n\n\n
    4. WilmerHale. (2002, September 13). Adequate written description with provisional patent applications.<\/em> https:\/\/www.wilmerhale.com\/insights\/publications\/adequate-written-description-with-provisional-patent-applications-september-13-2002<\/li>\n\n\n\n
    5. DrugPatentWatch. (2026). Drug patent strategy: The definitive guide for pharmaceutical IP teams, R&D leads, and institutional investors.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/optimizing-your-drug-patent-strategy-a-comprehensive-guide-for-pharmaceutical-companies\/<\/li>\n\n\n\n
    6. Alacrita Consulting. (n.d.). Pharmaceutical patent term extension: An overview.<\/em> https:\/\/www.alacrita.com\/whitepapers\/pharmaceutical-patent-term-extension-an-overview<\/li>\n\n\n\n
    7. Wikipedia. (2025). Sufficiency of disclosure.<\/em> https:\/\/en.wikipedia.org\/wiki\/Sufficiency_of_disclosure<\/li>\n\n\n\n
    8. National Law Review. (n.d.). Federal Circuit scrutinizes written description in provisional application.<\/em> https:\/\/natlawreview.com\/article\/federal-circuit-scrutinizes-written-description-provisional-application<\/li>\n\n\n\n
    9. Crouch, D. (2025, December 2). When juries don’t matter: Written description effectively becomes a question of law.<\/em> Patently-O. https:\/\/patentlyo.com\/patent\/2025\/12\/description-effectively-question.html<\/li>\n\n\n\n
    10. OC Patent Lawyer. (2024). Misconceptions of provisional patent applications.<\/em> https:\/\/ocpatentlawyer.com\/misconceptions-of-provisional-patent-applications\/<\/li>\n\n\n\n
    11. Pharma Lesson Masterclass. (2026). US patent filing strategies for pharmaceutical products.<\/em> https:\/\/courses.pharmalesson.com\/us-patent-filing-strategies-for-pharmaceutical-products\/<\/li>\n\n\n\n
    12. United States Patent and Trademark Office. (n.d.). MPEP \u00a7 2163: Guidelines for the examination of patent applications under the 35 U.S.C. 112(a) written description requirement.<\/em> https:\/\/www.uspto.gov\/web\/offices\/pac\/mpep\/s2163.html<\/li>\n\n\n\n
    13. Vici Health Sciences. (2025). Creating formulation intellectual property during drug development: FAQ.<\/em> https:\/\/vicihealthsciences.com\/creating-formulation-intellectual-property-during-drug-development-faq\/<\/li>\n\n\n\n
    14. DrugPatentWatch. (2025). Strategic imperatives: Leveraging patent pending data for competitive advantage in the pharmaceutical industry.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/leveraging-patent-pending-data-for-pharmaceuticals\/<\/li>\n\n\n\n
    15. Markovic, M., & Fr\u00f6hlich, B. (2024). The significance of provisional patent applications in protecting early-stage inventions: A legal and empirical analysis.<\/em> IIC \u2013 International Review of Intellectual Property and Competition Law. https:\/\/link.springer.com\/article\/10.1007\/s40319-024-01521-0<\/li>\n\n\n\n
    16. DrugPatentWatch. (2026). The predictive pipeline: The complete technical guide to AI-driven patent intelligence for pharmaceutical R&D timelines.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/the-predictive-pipeline-structuring-drug-development-timelines-with-ai-driven-patent-intelligence\/<\/li>\n\n\n\n
    17. DrugPatentWatch. (2025). How much does a drug patent cost? A comprehensive guide to pharmaceutical patent expenses.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/how-much-does-a-drug-patent-cost-a-comprehensive-guide-to-pharmaceutical-patent-expenses\/<\/li>\n\n\n\n
    18. DrugPatentWatch. (2026). Pharmaceutical patent term extensions and supplementary protection certificates: The complete technical reference for IP strategists, R&D leads, and institutional investors.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/understanding-patent-term-extensions-an-overview\/<\/li>\n\n\n\n
    19. Daniel Law Offices. (2026). Pharmaceutical patent law: A complete guide.<\/em> https:\/\/danielpatents.com\/pharmaceutical-patent-law-a-complete-guide\/<\/li>\n\n\n\n
    20. DrugPatentWatch. (2026). Securing innovation: A comprehensive guide to drafting and prosecuting patent applications for biologic drugs.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/drafting-drug-patent-applications-for-biologic-drugs\/<\/li>\n\n\n\n
    21. Juno Therapeutics, Inc. v. Kite Pharma, Inc., 10 F.4th 1330 (Fed. Cir. 2021).<\/li>\n\n\n\n
    22. DrugPatentWatch. (2026). Pharma patent filing strategies that maximize exclusivity: The complete IP playbook.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/filing-strategies-for-maximizing-pharma-patents\/<\/li>\n\n\n\n
    23. Hicks, A., & Bhattacharya, S. (2025). Navigating the USPTO’s AI inventorship guidance in AI-driven drug discovery.<\/em> PMC. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12317375\/<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

      Every week, a medicinal chemistry team somewhere identifies a promising compound, runs it past the IP group, and asks a […]<\/p>\n","protected":false},"author":1,"featured_media":38658,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38656","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38656"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38656\/revisions"}],"predecessor-version":[{"id":38659,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38656\/revisions\/38659"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38658"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}